Equities research analysts predict that Five Prime Therapeutics Inc (NASDAQ:FPRX) will post sales of $4.33 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Five Prime Therapeutics’ earnings, with the lowest sales estimate coming in at $2.83 million and the highest estimate coming in at $5.80 million. Five Prime Therapeutics reported sales of $5.77 million in the same quarter last year, which indicates a negative year over year growth rate of 25%. The business is expected to announce its next earnings report on Tuesday, November 5th.
On average, analysts expect that Five Prime Therapeutics will report full year sales of $17.37 million for the current year, with estimates ranging from $8.70 million to $26.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $51.25 million, with estimates ranging from $20.00 million to $139.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.09). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The company had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $5.53 million.
FPRX stock opened at $3.76 on Wednesday. Five Prime Therapeutics has a 1 year low of $3.22 and a 1 year high of $13.97. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87. The stock’s 50 day moving average price is $4.70 and its 200 day moving average price is $7.02. The firm has a market cap of $150.06 million, a P/E ratio of -0.91 and a beta of 2.57.
In other Five Prime Therapeutics news, major shareholder Bvf Partners L. P/Il purchased 16,000 shares of the business’s stock in a transaction on Friday, October 4th. The stock was bought at an average cost of $3.74 per share, for a total transaction of $59,840.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology acquired 601,482 shares of the company’s stock in a transaction dated Tuesday, October 8th. The shares were purchased at an average price of $3.74 per share, with a total value of $2,249,542.68. Insiders acquired a total of 1,142,552 shares of company stock valued at $4,278,395 over the last quarter. 7.10% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Bailard Inc. increased its holdings in shares of Five Prime Therapeutics by 23.8% during the 2nd quarter. Bailard Inc. now owns 13,000 shares of the biotechnology company’s stock worth $78,000 after buying an additional 2,500 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Five Prime Therapeutics by 1,691.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,374 shares of the biotechnology company’s stock worth $33,000 after buying an additional 5,074 shares during the last quarter. Alambic Investment Management L.P. acquired a new stake in shares of Five Prime Therapeutics during the 2nd quarter worth $69,000. Northern Trust Corp increased its holdings in shares of Five Prime Therapeutics by 2.8% during the 2nd quarter. Northern Trust Corp now owns 443,191 shares of the biotechnology company’s stock worth $2,672,000 after buying an additional 12,054 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC increased its holdings in shares of Five Prime Therapeutics by 101.9% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 24,066 shares of the biotechnology company’s stock worth $145,000 after buying an additional 12,146 shares during the last quarter. Institutional investors and hedge funds own 74.23% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.